Insurance, Medical Health Aged Care 30/09/2025 09:13

GMHBA celebrates fourth consecutive Canstar Award win with national recognition for Outstanding Value

GMHBA Limited < 1 mins read

< 1 mins read

Great news,

We’re excited to share a new achievement with you:

GMHBA celebrates fourth consecutive Canstar Award win with national recognition for Outstanding Value

Not-for-profit health fund GMHBA has once again been recognised by leading consumer comparison site Canstar, taking home six awards for providing outstanding value health insurance in 2025.

Read more

Contact details:

GMHBA Head of Corporate Communications Meg Rayner

0458 418 823 or [email protected]

For the latest announcements and updates visit GMHBA Media Centre.

More from this category

Medical Health Aged Care
19/12/2025
09:05

Royal Australian College of GPs

RACGP celebrates WA excellence in general practice at awards

The Royal Australian College of General Practitioners (RACGP) WA Faculty has honoured outstanding contributions to general practice at its annual awards ceremony, celebrating leaders, educators, registrars, and practices across the state. The evening provided the opportunity to celebrate the College’s highest honour, the Rose-Hunt Award, awarded during GP25, which was presented to WA GP, Adjunct Associate Professor Frank R Jones, recognising his 45 years of service to general practice, including 40 years at Murray Medical Centre in Mandurah. Professor Jones has worked across rural, procedural, and community settings and held numerous leadership roles within the RACGP, including President, Vice President,…

Contains:

Medical Health Aged Care
18/12/2025
22:11

BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

Contains:

Medical Health Aged Care
18/12/2025
19:11

Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.

Book a demo Explore our plans